Si-Bone Inc
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFu… Read more
Si-Bone Inc (SIBN) - Net Assets
Latest net assets as of September 2025: $172.13 Million USD
Based on the latest financial reports, Si-Bone Inc (SIBN) has net assets worth $172.13 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($234.27 Million) and total liabilities ($62.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $172.13 Million |
| % of Total Assets | 73.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1.42% |
| 10-Year Change | 5064.37% |
| Growth Volatility | 1152.5 |
Si-Bone Inc - Net Assets Trend (2013–2024)
This chart illustrates how Si-Bone Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Si-Bone Inc (2013–2024)
The table below shows the annual net assets of Si-Bone Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $166.96 Million | -1.42% |
| 2023-12-31 | $169.38 Million | +72.30% |
| 2022-12-31 | $98.30 Million | -26.87% |
| 2021-12-31 | $134.42 Million | -20.63% |
| 2020-12-31 | $169.36 Million | +168.80% |
| 2019-12-31 | $63.01 Million | -30.14% |
| 2018-12-31 | $90.19 Million | +169.71% |
| 2017-12-31 | $-129.38 Million | -18.99% |
| 2016-12-31 | $-108.73 Million | -3463.22% |
| 2015-12-31 | $3.23 Million | -53.09% |
| 2014-12-31 | $6.89 Million | +516.94% |
| 2013-12-31 | $-1.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Si-Bone Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39121800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $244.00K | 0.15% |
| Other Components | $598.07 Million | 358.20% |
| Total Equity | $166.96 Million | 100.00% |
Si-Bone Inc Competitors by Market Cap
The table below lists competitors of Si-Bone Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MedCap AB (publ)
ST:MCAP
|
$507.41 Million |
|
MorningStar Partners, L.P.
NYSE:TXO
|
$507.44 Million |
|
Jiangxi Ganneng Co Ltd
SHE:000899
|
$507.45 Million |
|
Pell Bio-Med Technology Co., Ltd.
TW:6949
|
$507.62 Million |
|
CGN Nuclear Technology Development Co Ltd
SHE:000881
|
$507.24 Million |
|
Senton Energy Co. Ltd. A
SHE:001331
|
$507.09 Million |
|
Kunshan Guoli Electronic Technology Co Ltd
SHG:688103
|
$507.07 Million |
|
Ur Energy Inc
NYSE MKT:URG
|
$506.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Si-Bone Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,375,000 to 166,964,000, a change of -2,411,000 (-1.4%).
- Net loss of 30,913,000 reduced equity.
- Share repurchases of 2,154,000 reduced equity.
- Other comprehensive income decreased equity by 91,000.
- Other factors increased equity by 30,747,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.91 Million | -18.51% |
| Share Repurchases | $2.15 Million | -1.29% |
| Other Comprehensive Income | $-91.00K | -0.05% |
| Other Changes | $30.75 Million | +18.42% |
| Total Change | $- | -1.42% |
Book Value vs Market Value Analysis
This analysis compares Si-Bone Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.72 | $12.84 | x |
| 2014-12-31 | $2.58 | $12.84 | x |
| 2015-12-31 | $0.13 | $12.84 | x |
| 2016-12-31 | $-7.02 | $12.84 | x |
| 2017-12-31 | $-9.33 | $12.84 | x |
| 2018-12-31 | $5.67 | $12.84 | x |
| 2019-12-31 | $2.55 | $12.84 | x |
| 2020-12-31 | $5.83 | $12.84 | x |
| 2021-12-31 | $4.06 | $12.84 | x |
| 2022-12-31 | $2.87 | $12.84 | x |
| 2023-12-31 | $4.41 | $12.84 | x |
| 2024-12-31 | $4.03 | $12.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Si-Bone Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.49%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.38x
- Recent ROE (-18.51%) is above the historical average (-127.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -12.56% | 2.72x | 0.00x | $-5.99 Million |
| 2014 | -403.45% | -69.42% | 1.38x | 4.21x | $-28.50 Million |
| 2015 | -870.83% | -68.38% | 1.14x | 11.15x | $-28.48 Million |
| 2016 | 0.00% | -48.90% | 1.07x | 0.00x | $-9.72 Million |
| 2017 | 0.00% | -48.01% | 1.34x | 0.00x | $-10.10 Million |
| 2018 | -19.35% | -31.51% | 0.40x | 1.54x | $-26.47 Million |
| 2019 | -60.95% | -57.06% | 0.58x | 1.86x | $-44.70 Million |
| 2020 | -25.80% | -59.54% | 0.33x | 1.32x | $-60.63 Million |
| 2021 | -42.09% | -62.75% | 0.47x | 1.42x | $-70.01 Million |
| 2022 | -62.31% | -57.57% | 0.68x | 1.60x | $-71.09 Million |
| 2023 | -25.59% | -31.20% | 0.60x | 1.36x | $-60.27 Million |
| 2024 | -18.51% | -18.49% | 0.73x | 1.38x | $-47.61 Million |
Industry Comparison
This section compares Si-Bone Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Si-Bone Inc (SIBN) | $172.13 Million | 0.00% | 0.36x | $507.40 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |